Analysis of pediatric outpatient visits uncovers disparities in molluscum contagiosum treatment across medical specialties in the United States


Published: 11 October 2023
Abstract Views: 297
PDF: 199
HTML: 2
Publisher's note
All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher.

Authors

Molluscum contagiosum (MC) is a common viral infection that affects the skin of children. In this study, treatment regimens and demographic information for MC patients across US medical specialties were compared. We discovered an average of 471,383 pediatric MC visits annually using the National Ambulatory Medical Care Survey database from 2000 to 2016. Non-Hispanics (82.9%) and Caucasians (91.0%) made up the majority of the visitors. The majority of cases were handled by pediatricians (46.5%), family medicine doctors (10.6%), and dermatologists (36.7%). Compared to pediatricians, dermatologists saw a higher percentage of Caucasian patients (95% vs.84%) and patients with private insurance (83% vs. 73%). Patients were more likely to see family medicine doctors (55.0%) in non-metropolitan areas than pediatricians (26.4%) or dermatologists (16.3%). Dermatologists were less likely than pediatricians (38%) to favor spontaneous resolution (70%). Dermatologists favored terpenoids (20%), imiquimod (12%), and curettage (10%), while pediatricians primarily used terpenoids (12%), steroids (4%), and imiquimod (4%). The majority of MC cases are managed by pediatricians; however, treatment approaches deviate markedly from recommended best practices.


Chen X, Anstey AV, Bugert JJ. Molluscum contagiosum virus infection. Lancet Infect Dis 2013;13:877-88.

Olsen JR, Gallacher J, Piguet V, Francis NA. Epidemiology of molluscum contagiosum in children: a systematic review. Fam Pract 2014;31:130-6.

Tyring SK. Molluscum contagiosum: the importance of early diagnosis and treatment. Am J Obstet Gynecol 2003;189:S12-6.

Basdag H, Rainer BM, Cohen BA. Molluscum contagiosum: to treat or not to treat? Experience with 170 children in an outpatient clinic setting in the northeastern United States. Pediatr Dermatol 2015;32:353-7.

Lee R, Schwartz RA. Pediatric molluscum contagiosum: reflections on the last challenging poxvirus infection, Part 1. Cutis 2010;86:230-6.

Eichenfield L, Hebert A, Mancini A, et al. Therapeutic approaches and special considerations for treating molluscum contagiosum. J Drugs Dermatol 2021;20:1185-90.

Moreno MA, Goniu N, Moreno PS, Diekema D. Ethics of social media research: common concerns and practical considerations. Cyberpsychol Behav Soc Netw 2013;16:708-13.

Molino AC, Fleischer AB, Feldman SR. Patient demographics and utilization of health care services for molluscum contagiosum. Pediatr Dermatol 2004;21:628-32.

Chapa PJ, Mavura DR, Philemon R, et al. Contributing factors and outcome after cryotherapy of molluscum contagiosum among patients attending tertiary hospital, northern Tanzania: a descriptive prospective cohort study. Dermatol Res Pract 2021;2021:9653651.

Hanna D, Hatami A, Powell J, et al. A prospective randomized trial comparing the efficacy and adverse effects of four recognized treatments of molluscum contagiosum in children. Pediatr Dermatol 2006;23:574-9.

Badri T, Gandhi GR. Molluscum Contagiosum. In: StatPearls. eds. Treasure Island (FL): StatPearls Publishing; 2022.

Cathcart S, Coloe J, Morrell DS. Parental satisfaction, efficacy, and adverse events in 54 patients treated with cantharidin for molluscum contagiosum infection. Clin Pediatr (Phila) 2009;48:161-5.

Harel A, Kutz AM, Hadj-Rabia S, Mashiah J. To treat molluscum contagiosum or not-curettage: an effective, well-accepted treatment modality. Pediatr Dermatol 2016;33:640-5.

Guzman AK, Schairer DO, Garelik JL, Cohen SR. Safety and efficacy of topical cantharidin for the treatment of pediatric molluscum contagiosum: a prospective, randomized, doubleblind, placebo-controlled pilot trial. Int J Dermatol 2018;57:1001-6.

Syed TA, Lundin S, Ahmad M. Topical 0.3% and 0.5% podophyllotoxin cream for self-treatment of molluscum contagiosum in males. A placebo-controlled, double-blind study. Dermatol 1994;189:65-8.

Theos AU, Cummins R, Silverberg NB, Paller AS. Effectiveness of imiquimod cream 5% for treating childhood molluscum contagiosum in a double-blind, randomized pilot trial. Cutis 2004;74:134-8, 141-2.

Osio A, Deslandes E, Saada V, et al. Clinical characteristics of molluscum contagiosum in children in a private dermatology practice in the greater Paris area, France: a prospective study in 661 patients. Dermatology 2011;222:314-20.

Netchiporouk E, Cohen BA. Recognizing and managing eczematous id reactions to molluscum contagiosum virus in children. Pediatrics 2012;129:e1072-5.

Rajalingam, K., Chen, W.-S., & Lin, A. (2023). Analysis of pediatric outpatient visits uncovers disparities in molluscum contagiosum treatment across medical specialties in the United States. Dermatology Reports, 16(2). https://doi.org/10.4081/dr.2023.9851

Downloads

Download data is not yet available.

Citations